Week in Review: Zhejiang Medicine to Develop Ambrx, Inc. Breast Cancer Drug

Published: Jun 24, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 22, 2013 --Zhejiang Medicine Co. will collaborate with Ambrx of San Diego to develop an Ambrx molecule that targets Her2-positive breast cancer; Suzhou Ribo Life Sciences acquired China Rights to Life Technologies’ Invivofectamine® Rx delivery technology for siRNA therapeutics; Shanxi CY Pharma announced plans to purchase a stake of at least 80% in Hangzhou Baoling Group Co., Ltd.; BioClinica®, a clinical trial services company headquartered in the US, formed a cardiac safety partnership with TEDA International Cardiovascular Hospital in Tianjin; Sichuan BoXin LaiTe Biotechnology signed a MOU to advance drug development projects with the University of British Columbia; and China’s chief drug safety regulator, the CFDA, felt compelled to have a meeting with Johnson & Johnson about product recalls. More details….

Stock Symbols: (SHA: 600216) (NSDQ: LIFE) (SHE: 300254) (NYSE: JNJ)

Help employers find you! Check out all the jobs and post your resume.

Back to news